| Patent application number | Description | Published |
|---|
| 20100196313 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 08-05-2010 |
| 20100196314 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 08-05-2010 |
| 20120059355 | METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION - A reinforcement region is formed within the myocardium by introducing a delivery device through a vessel wall to a treatment site within a myocardium. A biomaterial is then delivered to the treatment site as the delivery device is withdrawn from the treatment site to form the reinforcement regions. Formation of the reinforcement region may further include introducing a delivery device through a vessel wall to a region within a myocardium such that the delivery device is positioned within the myocardium substantially parallel to a wall of the myocardium. A biomaterial may be delivered into a space formed within the region by the delivery device. The reinforcement region may be formed around an infarct tissue region of a myocardium to reinforce the damaged tissue. | 03-08-2012 |
| 20120237477 | METHODS AND COMPOSITIONS FOR TREATING POST-MYOCARDIAL INFARCTION DAMAGE - Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area. | 09-20-2012 |
| Patent application number | Description | Published |
|---|
| 20080206207 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 08-28-2008 |
| 20090075933 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 03-19-2009 |
| 20120064098 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 03-15-2012 |
| 20120148609 | INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 06-14-2012 |
| 20120148668 | INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 06-14-2012 |
| 20120157751 | INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 06-21-2012 |
| 20120225040 | METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications. | 09-06-2012 |
| 20120225041 | METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications. | 09-06-2012 |
| 20120251508 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 10-04-2012 |
| 20120252089 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 10-04-2012 |
| Patent application number | Description | Published |
|---|
| 20090024401 | Involvement of a Novel Nuclear-Encoded Mitochondrial Poly(A) Polymerase PAPD1 in Extreme Obesity-Related Phenotypes in Mammals - Aspects of the present invention also provide novel compositions and methods based on novel PAPD1 single nucleotide polymorphisms selected from the group consisting of AAFC02034082.1:g.9224G>A, g.9330A>C, g.9367G>C, g.9419A>C, g.9435T>G, g.9409[(G)4]+[(G)5], g.10084T>C, g.10228G>T, c.10326C>T and c.10364A>G, which may provide novel markers for intramuscular fat deposition. Additional aspects provide for novel methods which may comprise marker-assisted selection or marker-assisted management to improve intramuscular fat deposition in cattle. | 01-22-2009 |
| 20090092978 | ASSOCIATION OF UQCRC1SNPs WITH FAT DEPOSITION AND FATTY ACID COMPOSITION - The present invention relates to the identification of single nucleotide polymorphisms (SNPs) in a ubiquinol-cytochrome c reductase core protein I (UQCRC1) gene and its associations association with fat deposition and fatty acid composition. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data, haplotype data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations. | 04-09-2009 |
| 20090254388 | Urotensin 2 and its Receptor as Candidate Genes for Beef Marbling Score, Ribeye Area and Fatty Acid Composition - The present invention relates to the identification of single nucleotide polymorphisms (SNPs) in urotensin II (UTS2) and urotensin 2 receptor (UTS2R) genes and their associations with beef marbling score (BMS), ribeye area (REA), amounts of saturated (rSFA) and monounsaturated (rMUFA), and Δ | 10-08-2009 |
